PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.05%
Negative revenue growth while Medical - Pharmaceuticals median is 3.02%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-4.70%
Negative gross profit growth while Medical - Pharmaceuticals median is 1.70%. Seth Klarman would suspect poor product pricing or inefficient production.
-30.38%
Negative EBIT growth while Medical - Pharmaceuticals median is -0.00%. Seth Klarman would check if external or internal factors caused the decline.
-24.93%
Negative operating income growth while Medical - Pharmaceuticals median is -0.37%. Seth Klarman would check if structural or cyclical issues are at play.
-19.88%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-19.88%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-19.88%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.13%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.01%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.62%
10Y revenue/share CAGR near Medical - Pharmaceuticals median of 36.89%. Charlie Munger might expect stable industry trends guiding long-term growth.
50.86%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 18.29%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
25.47%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 13.23%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.16%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 16.53% over a decade. Joel Greenblatt might see a standout compounder of earnings.
22.93%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.53%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
21.41%
Positive 3Y CAGR while Medical - Pharmaceuticals median is negative. Peter Lynch sees a big short-term advantage vs. peers struggling with profit declines.
173.04%
Equity/share CAGR of 173.04% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
113.90%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 19.68%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
53.95%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 9.51%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
122.22%
Dividend/share CAGR of 122.22% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
128.57%
5Y dividend/share CAGR of 128.57% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
77.78%
3Y dividend/share CAGR of 77.78% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
49.38%
AR growth of 49.38% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
6.80%
Inventory growth of 6.80% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
0.73%
Asset growth exceeding 1.5x Medical - Pharmaceuticals median of 0.33%. Joel Greenblatt confirms strong expansions matched by adequate returns on those assets.
2.86%
BV/share growth of 2.86% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-7.13%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
1.19%
SG&A dropping significantly vs. Medical - Pharmaceuticals median. Joel Greenblatt sees near-term margin upside but checks for underinvestment risk.